A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma

NCT05234684 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

DRUG: Orelabrutinib + R-CHOP
DRUG: Placebo + R-CHOP

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.